The clinical screenings for newborns have been helpful to diagnose such hemoglobinopathies. Specific regions of the gene encoding the beta globin chain of hemoglobin (HBB gene), such as coding regions, intro-exon boundaries, proximal promoter, 5' and 3' untranslated regions, and intronic mutations IVS-II-654, IVS-II-705 and IVS-II-745 can also be sequenced (target sequencing) for accurate diagnosis. However, mutations and deletions outside these routine targets can be easily missed. Herein, we report a complex case of a 6-week-old newborn identified with a rare HBB variant, Hb Hope, concurrent with two heterozygous deletions of HBB promoter and exons 1-2, leading to simultaneous beta-thalassemia. These deletions failed to be identified initially via ordinary deletion/duplication test. Methods: CE-HPLC, IEF and multiplex ligation-dependent probe amplification of the beta globin gene cluster (HBB, HBD, HBG1, HBG2, HBE1) and its locus control region were used for laboratory diagnostic. Results: Due to co-migration and co-elution, screening for hemoglobinopathies via IFE and CE-HPLC in this patient revealed only Hb F and absence of Hb A. However, the beta globin gene full sequencing identified Hb Hope [β136(H14) Gly→Asp (GGT→GAT)], a rare HBB variant which is not clinically significant. Furthermore, beta globin gene complete sequencing also revealed two additional deletions: HBB promoter on one allele and deletion of exons 1-2 on the other allele. Therefore, the diagnosis of concurrent beta-thalassemia major was also made. Conclusion: Due to the analytical limitation of current laboratory tests, more specific laboratory evaluations are occasionally necessary to establish an accurate diagnosis in complex cases. Introduction: It has been identified that the nondiagnostic/ unsatisfactory rate (ND/UNS) of thyroid fine needle aspirations (FNAs) is dependent on the operators who provide the samples; however, little is published on whether the diagnostic interpretation of the pathologists contributes to the problem of suboptimal thyroid samples. Methods: A total of 679 thyroid FNAs sent to St. Boniface Hospital in Winnipeg, Canada, were randomly selected and reviewed retrospectively. Cases read by pathologists who had interpreted <20 cases were excluded, resulting in 628 cases randomly assigned to 12 pathologists. The final cytologic diagnoses were recorded, and the overall ND/ UNS was determined for the group as well as for each individual pathologist. Conclusions: Of the 628 cases, 145 were signed out by the pathologist as ND/UNS (23%). The average number of FNAs per pathologist was 52, with the individual numbers ranging from 22 to 103 FNAs per pathologist. The individual ND/UNS for each pathologist ranged
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